Axxam integrates BiomimX uBeat® Organ-on-Chip technology into its drug discovery services
- 4 days ago
- 2 min read
Updated: 3 days ago
16 July 2026
Milan-based CRO Axxam and organ-on-a-chip developer BiomimX announce the integration of BiomimX' proprietary uBeat® technology into Axxam's drug discovery services, enhancing the CRO's ability to support clients with predictive and physiologically relevant testing models
Axxam clients include pharma and biotech companies, patient foundations, academic groups, cosmetics and fragrance industries who seek to identify and validate bioactive molecules. To meet these needs, Axxam leverages AI-powered data analysis and in vitro high-throughput screening. The combination of uBeat® organ-on-a-chip technology and AI-driven in silico lead de-risking is expected to reduce late-stage attrition, increase confidence in decision-making and accelerate the delivery of innovative therapies to patients.
“At Axxam, we believe that selecting the right experimental model at the right stage of drug discovery is essential for improving the probability of success,” said Ciriaco Maraschiello, CEO of Axxam. “The integration of BiomimX’s uBeat® technology significantly strengthens our ability to support clients with increasingly predictive and physiologically relevant models, creating a seamless path from high-throughput screening to advanced Organ-on-Chip systems. This collaboration further reinforces our commitment to delivering innovative, human-relevant drug discovery solutions.”
“New Approach Methodologies are gaining real momentum, and their value extends across the whole discovery process, from target validation and disease modelling through to safety assessment” said Paola Occhetta, CEO and Co-Founder of BiomimX. “Partnering with an established discovery player like Axxam is exactly how Organ-on-Chip technology reaches the researchers who need it, by combining Axxam’s power to screen at scale with advanced, human-relevant models that show how a candidate behaves in functionally mature human tissue. Together we can give clients a clearer view of both efficacy and safety.”
In the first stages, the collaboration will focus on cardiovascular disease research and cardiotoxicity, to support target validation, disease modeling, and drug efficacy and safety testing.
For weekly news, trends and insights on human‑based in vitro approaches, explore your access options.
